More drug discovery startups are advancing to the clinical stage, while funding has become more difficult from the middle stage onward. Some are also seeking to expand overseas in pursuit of funding.
The number of drug discovery startups advancing to the clinical stage is reportedly increasing, bringing changes in the funding environment according to the stage of pipeline development into focus.
Funding is said to be particularly difficult from the middle stage onward, creating a need for new strategies to secure financing.
Some companies are considering or pursuing overseas expansion in search of funding, making domestic and overseas financing and market expansion key areas of focus going forward.